Navigation Links
Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
Date:10/28/2009

$100 M venture capital affiliate of Amgen Inc. with approximately 15 portfolio companies. He had also been responsible for Amgen's in- and outlicensing transactions group and Amgen's Corporate Alliance Management function. Mr. Mackey received his undergraduate degree from Harvard University and his law degree from the University of California, Berkeley's Boalt Hall School of Law.

Recent scientific and business accomplishments at Santaris Pharma A/S include a breakthrough in medical science and new collaborations. Santaris Pharma A/S is the first company to advance a microRNA-targeted therapy into human clinical trials. The drug SPC3649 specifically targets microRNA-122 (miR-122), a host factor for Hepatitis C virus replication. A single-dose Phase 1 trial in healthy volunteers has been completed and the drug continues to move forward in clinical trials.

Santaris Pharma A/S recently announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-targeted medicines to treat rare genetic disorders. This collaboration adds to the growing list of mRNA and microRNA drug discovery and development partnerships, which includes Wyeth (delivery of lead candidates against up to ten targets), GlaxoSmithKline (four viral disease drug candidates) and Enzon Pharmaceuticals (eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetically modified chemical versions of the normal nucleic acid building blocks of ribonucleic acids (RNA). These modified chemical versions called LNAs improve the drug-like qualities of resulting therapeutics (oligonucleotides) by boosting resistance to metabolism, increasing half-life and improving tissue uptake. LNA-based therapeutics demonstrate improved binding affinity to their target RNA, which increases pot
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 ... first-in-class aminomethylcycline (AMC). The Phase 2 study compared,safety ... of PTK 0796 to,Zyvox(R) in the treatment of ... Paratek,s trial met its primary safety and,tolerability endpoint, ...
... United Kingdom, Oct. 24 Minster,Pharmaceuticals plc (AIM: ... psychiatric disorders, is pleased to announce positive,results from ... in the prevention,of migraine with aura. The median ... in patients receiving tonabersat when compared with placebo. ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 2Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 3
(Date:11/24/2014)... Westbury, New York (PRWEB) November 24, 2014 ... recently contacted by the Family and Children's Association ... products such as soap, shampoo, mouthwash and other such ... senior citizens who are home bound, living in nursing ... are intended to greatly enhance the well being of ...
(Date:11/24/2014)... 24, 2014 ReAdmission Solutions, LLC ... management services to health plans, hospitals, and accountable ... Management software suite. ReAdmission Solutions will use ... program to reduce patients' avoidable readmissions to hospitals. ... Care Management, Utilization Management, and Appeals & Grievances. ...
(Date:11/23/2014)... 2014 iFitDress.com, a well-known wedding dress manufacturer, ... gowns . They are now offered at deeply discounted ... last from now to Dec. 15. The main purpose of ... the company’s high quality items are ideal options for ladies ... sum of money. All its new mint cocktail dresses are ...
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... FREMONT, Calif., June 2 Allscripts (Nasdaq: ... connectivity solutions for physicians and hospitals, and SYNNEX Corporation ... services company, today announced that SYNNEX, through its SYNNEX ... Health Record (EHR) to Allscripts authorized resellers who are ...
... Remember CPR Instructions , , CHANDLER, Ariz., June 2 Years ... you knew what to do if someone was having a heart attack, ... How often? And time is of the essence. Do you really have ... Now a small business has come forward with a simple way to ...
... One stool sample can be used to perform several screens, ... testing of a person,s stool can accurately screen for more ... found. , While DNA stool testing has been successfully ... Mayo Clinic have found that the noninvasive screening is also ...
... Philadelphia, 2 June 2009 A closer look at ... thoracic transplantation is required, according to an educational advisory ... (ISHLT) in the July 2009 issue of The ... ), published by Elsevier. ...
... Tasty Way to do More for Your Heart , ... premier natural food company, today announced the addition of whole ... of foods. The new whole wheat crackers are as delicious ... and antioxidants, making them the first nationally distributed crackers to ...
... Two studies from AstraZeneca (NYSE: AZN ... treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced ... compared with patients taking placebo over four weeks(1). NEXIUM ... and other symptoms associated with GERD. NEXIUM, in ...
Cached Medicine News:Health News:Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records 2Health News:Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records 3Health News:Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records 4Health News:Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records 5Health News:Convenient Safety Magnets Tell You What To Do In An Emergency 2Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:More stringent evaluation on the use of generic medications in thoracic transplantation 2Health News:Kashi Company Debuts Heart to Heart(TM) Whole Grain Crackers 2Health News:Kashi Company Debuts Heart to Heart(TM) Whole Grain Crackers 3Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 2Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 3Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 4Health News:AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances 5
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
1000 L, Bulk, blue Recommended for 500 and 1000 L pipettes....
Medicine Products: